Clinical Trial Update: TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of transarterial chemoembolization (TACE) with camrelizumab and apatinib for advanced hepatocellular carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)
• TACE

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN